Nature Webinar

Sep 21, 2021

Register for Isogenica’s upcoming webinar

Join Isogenica for the upcoming webinar with Nature on ‘VHH as building blocks for immune and tumour cell-targeting’, presented by Isogenica’s CSO Bill Eldridge. 

This presentation will expand on the recent advances in the field of VHH-based therapeutics and highlight particular therapy applications where a naturally monovalent antibody domain structure can be combined to generate the next generation of biologics.

Specifically, it will answer the following questions:

What are the potential applications of VHH antibodies?

What are VHH and their unique characteristics which make them applicable as immune cell recruiting agents?

VHH-based Bispecifics: what differentiates them from the existing classes of bispecific antibodies. ​

Register for the webinar now to learn all about the incredible potential and latest developments of VHH in next generation therapeutics.

Further Information

Isogenica has developed LlamdA™ (single domain VHH) therapeutic antibodies from its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.  Over the last four years Isogenica has entered into eight significant partnerships, leveraging its libraries, technologies and expertise to build a broad pipeline of programs that are now advancing into pre-clinical and early clinical development with our partners.”


Mandeep Sehmi,
Business Development

T +44 1799 533 680


Contact us